■血液透析(HD)患者易患身体疾病,他们2019年冠状病毒病(COVID-19)的发生可能导致更不利的预后。然而,SARS-CoV-2(Omicron变异型)感染对HD患者预后的影响尚不清楚.本研究旨在探讨Omicron变异型感染对HD患者预后的影响。
符合条件的参与者是在上海大规模爆发COVID-19(Omicron变种)期间接受维持性HD治疗的患者,中国,2022年4月7日至5月30日。根据参与者的SARS-CoV-2感染状况,HD患者分为两组:COVID-19组和非COVID-19组.评估的主要结果是住院死亡率,次要结果包括严重病例的发生率,入院重症监护,住院时间,和血液指数。采用比较分析和多因素logistic回归进行统计学分析。
■这项研究招募了588名HD患者,其中COVID-19组199例,非COVID-19组389例。在COVID-19组中,死亡率为8.45%(17/199),而在非COVID-19组中,发生率为3.34%(13/389)(p<0.05)。与非COVID-19组相比,COVID-19组死亡率的风险比(RR)为2.56(1.27-5.15),95%置信区间(CI),和绝对风险差(ARD),95%CI为5.20%(1.34%-9.06%)。多因素logistic回归证实Omicron变异体是HD患者死亡的危险因素。此外,COVID-19组的重症病例比例更高,重症监护入院,低钙血症和高磷血症以及较长的住院时间,与非COVID-19组相比(p<0.05)。
■Omicron变异型感染与HD患者死亡风险增加相关,Omicron感染使HD患者的预后恶化。在持续的COVID-19大流行期间,增强针对SARS-CoV-2的免疫保护对于HD患者至关重要。
UNASSIGNED: Haemodialysis (HD) patients are predisposed to physical ailments, and their occurrence of coronavirus disease 2019 (COVID-19) could potentially lead to a more unfavourable prognosis. However, the impact of SARS-CoV-2 (Omicron variant) infection on the prognosis of HD patients remains unclear. This study aimed to explore the impact of Omicron variant infection on the prognosis of HD patients.
UNASSIGNED: Eligible participants were patients undergoing maintenance HD treatment during a large-scale outbreak of COVID-19 (Omicron variant) in Shanghai, China, from April 7 to May 30, 2022. According to SARS-CoV-2 infection status of participants, the HD patients were divided into two groups: a COVID-19 group and a non-COVID-19 group. The primary outcome assessed was in-hospital mortality, and secondary outcomes encompassed the incidence of severe cases, admission to intensive care, length of hospital stay, and blood indices. Statistical analysis was conducted by comparative analysis and multiple logistic regression.
UNASSIGNED: This study recruited 588 HD patients, including 199 cases in the COVID-19 group and 389 in the non-COVID-19 group. In the COVID-19 group, the mortality rate was 8.45% (17/199), whereas in the non-COVID-19 group, the rate was 3.34% (13/389) (p < 0.05). Compared with the non-COVID-19 group, the COVID-19 group had a risk ratio (RR) with 95% confidence interval (CI) of 2.56 (1.27-5.15) for mortality, and the absolute risk difference (ARD) with 95% CI of 5.20% (1.34%-9.06%). Multiple logistic regression confirmed Omicron variant as a risk factor for mortality among HD patients. Additionally, the COVID-19 group had a higher proportion of severe cases, intensive care admission, hypocalcaemia and hyperphosphatemia and longer hospitalization duration, compared to the non-COVID-19 group (p < 0.05).
UNASSIGNED: Omicron variant infection was associated with increased mortality risk in HD patients, and Omicron infection worsen the prognosis of HD patients. Enhancing immune protection against SARS-CoV-2 is crucial for HD patients during the ongoing COVID-19 pandemic.